---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-23-000015"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:24:41.138850+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer

## Summary
- Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.
- 4-month progression-free survival rate of 77% and overall response rate of 22%; no drug-related discontinuations observed.
- Compared to historical KEYNOTE-775 trial: ONA-XR+ANA showed higher 4-month PFS (77% vs 42% chemo, 67% Lenvima+Keytruda) and lower discontinuation (0% vs 8% and 33%).
- Drug well-tolerated with mainly Grade 1-2 adverse events; updated data expected in Q2 2023.

## SEC filing metadata
- accession: 0001842952-23-000015
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000015/0001842952-23-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000015/cntx-20230206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-23-000015
- JSON: https://secwatch.observer/filing/0001842952-23-000015.json
- Plain text: https://secwatch.observer/filing/0001842952-23-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.